CN1521161A - Preparation of Oxaliplatin - Google Patents
Preparation of Oxaliplatin Download PDFInfo
- Publication number
- CN1521161A CN1521161A CNA031039081A CN03103908A CN1521161A CN 1521161 A CN1521161 A CN 1521161A CN A031039081 A CNA031039081 A CN A031039081A CN 03103908 A CN03103908 A CN 03103908A CN 1521161 A CN1521161 A CN 1521161A
- Authority
- CN
- China
- Prior art keywords
- oxaliplatin
- platinum
- dach
- cis
- cyclohexanediamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001756 oxaliplatin Drugs 0.000 title claims abstract description 30
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- XNGYKPINNDWGGF-UHFFFAOYSA-L silver oxalate Chemical compound [Ag+].[Ag+].[O-]C(=O)C([O-])=O XNGYKPINNDWGGF-UHFFFAOYSA-L 0.000 claims abstract description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 27
- 102100028735 Dachshund homolog 1 Human genes 0.000 claims description 20
- 101000915055 Homo sapiens Dachshund homolog 1 Proteins 0.000 claims description 20
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims description 20
- 229910052697 platinum Inorganic materials 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 239000012265 solid product Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- UGQDIOUBRRLHMW-UHFFFAOYSA-N cyclohexane-1,1-diamine;platinum(2+) Chemical compound [Pt+2].NC1(N)CCCCC1 UGQDIOUBRRLHMW-UHFFFAOYSA-N 0.000 abstract 1
- 230000006837 decompression Effects 0.000 abstract 1
- 239000003999 initiator Substances 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Substances OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- HNKLPNDFOVJIFG-UHFFFAOYSA-N oxalic acid;platinum Chemical compound [Pt].OC(=O)C(O)=O HNKLPNDFOVJIFG-UHFFFAOYSA-N 0.000 description 1
- -1 platinum group metal complex Chemical class 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Abstract
Description
技术领域technical field
本发明涉及抗肿瘤药物奥沙利铂的合成制备。The invention relates to the synthesis and preparation of antitumor drug oxaliplatin.
背景技术Background technique
奥沙利铂属铂族金属配合物,是继顺铂、卡铂之后的新一代铂类抗肿瘤药物。奥沙利铂又名草酸铂,英文名Oxaliplatin,缩写为L-OHP,全称为顺式-草酸(反式-(-)-1,2-环己二胺)合铂(II)[cis-oxalato(trans-(1R,2R)-(-)-1,2-diaminocyclohexane)platinum(II)],分子量为397.33,化学结构式:Oxaliplatin is a platinum group metal complex and is a new generation of platinum-based antineoplastic drugs after cisplatin and carboplatin. Oxaliplatin, also known as oxaliplatin, English name Oxaliplatin, abbreviated as L-OHP, full name cis-oxalic acid (trans-(-)-1,2-cyclohexanediamine) platinum(II)[cis- oxalato(trans-(1R,2R)-(-)-1,2-diaminocyclohexane)platinum(II)], molecular weight is 397.33, chemical structural formula:
奥沙利铂最早由瑞士Debiopharm公司开发,1997年在法国获批准应用于临床,主要用于治疗转移性大肠直肠癌。目前已在多个国家或地区获批准应用于临床。美国FDA也认可批准治疗大肠直肠癌。奥沙利铂是以草酸根及反式-(-)-1,2环己胺(DACH)作配体与二价金属铂形成的配合物。《贵金属》2000年第21卷第1期刊载的“草酸铂的合成及其结构表征”一文中,报道了奥沙利铂的合成方法,其合成路线为:Oxaliplatin was first developed by Debiopharm in Switzerland and was approved for clinical use in France in 1997, mainly for the treatment of metastatic colorectal cancer. At present, it has been approved for clinical application in many countries or regions. The US FDA also approves the treatment of colorectal cancer. Oxaliplatin is a complex formed with oxalate and trans-(-)-1,2 cyclohexylamine (DACH) as ligands and divalent metal platinum. In the article "Synthesis and Structural Characterization of Platinum Oxalate" published in No. 1, Volume 21, 2000 of "Precious Metals", the synthesis method of oxaliplatin is reported, and the synthesis route is as follows:
《Drugs of the future》1989年第14卷第6期刊载的“Oxaliplatin”一文中也报道了奥沙利铂的合成方法,其工艺路线为:"Drugs of the future" also reported the synthesis method of Oxaliplatin in the article "Oxaliplatin" published in Volume 14, Issue 6, 1989. The process route is:
上述两篇文献公开的奥沙利铂的合成是以顺式-二氯环己二胺合铂(II)或顺式-二碘环己二胺合铂(II)为中间体,加硝酸银水解反应,然后过滤除去氯化银或碘化银沉淀,母液中加入草酸钾或草酸钠,反应后生成奥沙利铂水溶液,减压浓缩得奥沙利铂产品。这种制备技术由于采用多步化学反应,导致工艺流程冗长复杂,产品收率较低。The synthesis of oxaliplatin disclosed in the above two documents is to use cis-dichlorocyclohexanediamine platinum (II) or cis-diiodocyclohexanediamine platinum (II) as an intermediate, and add silver nitrate Hydrolysis reaction, and then filter to remove silver chloride or silver iodide precipitation, add potassium oxalate or sodium oxalate to the mother liquor, generate oxaliplatin aqueous solution after reaction, and concentrate under reduced pressure to obtain oxaliplatin product. Due to the use of multi-step chemical reactions in this preparation technology, the process flow is lengthy and complicated, and the product yield is low.
发明内容Contents of the invention
本发明目的在于提供一种工艺流程简便的奥沙利铂制备方法。The object of the present invention is to provide a kind of preparation method of oxaliplatin with simple and convenient technological process.
本发明的奥沙利铂制备方法,采用顺式-二氯(反式-(-)-1,2-环己二胺)合铂(II),其分子式Pt(DACH)Cl2,其结构式为:The preparation method of oxaliplatin of the present invention adopts cis-dichloro (trans-(-)-1,2-cyclohexanediamine) platinum (II), its molecular formula Pt(DACH)Cl 2 , its structural formula for:
或顺式-二碘(反式-(-)-1,2-环己二胺)合铂(II),其分子式Pt(DACH)I2,其结构式为:Or cis-diiodo(trans-(-)-1,2-cyclohexanediamine) platinum(II), its molecular formula is Pt(DACH)I 2 , and its structural formula is:
在40℃至75℃避光条件下与草酸银Ag2C2O4反应,两者的反应摩尔比为1∶1,得到奥沙利铂水溶液。React with silver oxalate Ag 2 C 2 O 4 under the condition of 40°C to 75°C protected from light, and the reaction molar ratio of the two is 1:1 to obtain an aqueous solution of oxaliplatin.
将上述反应制备得到的奥沙利铂水溶液置于蒸发容器中并降低蒸发容器内的压力,于40℃至75℃水浴加热浓缩奥沙利铂水溶液,可以得到奥沙利铂固体产品。The oxaliplatin aqueous solution prepared by the above reaction is placed in an evaporation container, the pressure in the evaporation container is reduced, and the oxaliplatin aqueous solution is heated and concentrated in a water bath at 40° C. to 75° C. to obtain a solid oxaliplatin product.
相应的化学反应式为:The corresponding chemical reaction formula is:
或
本发明的奥沙利铂制备方法与上述文献报道的方法相比,缩短了生产周期,简化了生产工序,操作简便,生产效率提高近10个百分点。Compared with the method reported in the above literature, the preparation method of oxaliplatin of the present invention shortens the production cycle, simplifies the production process, is easy to operate, and increases the production efficiency by nearly 10 percentage points.
一、试剂及材料1. Reagents and materials
1.Pt(DACH)I2,分子量为:563.08。采用将K2PtCl4溶于适量水中,加入过量的分析纯KI,30min后等当量加入DACH,2小时后过滤沉出的黄色沉淀,分别用水、乙醇及丙酮洗涤,70℃干燥,得Pt(DACH)I2产品,纯度≥98%。1. Pt(DACH)I 2 , molecular weight: 563.08. Dissolve K 2 PtCl 4 in an appropriate amount of water, add excess analytically pure KI, add DACH equivalently after 30 minutes, filter the precipitated yellow precipitate after 2 hours, wash with water, ethanol and acetone respectively, and dry at 70°C to obtain Pt( DACH) I 2 product, purity ≥ 98%.
2.Pt(DACH)Cl2,分子量为:380.17。采用将K2PtCl4溶于适量水中,等当量加入DACH,反应2小时,过滤析出的黄色沉淀,分别用水、乙醇及丙酮洗涤,70℃干燥,得Pt(DACH)Cl2产品,纯度≥98%。2. Pt(DACH)Cl 2 , molecular weight: 380.17. Dissolve K 2 PtCl 4 in an appropriate amount of water, add DACH in an equivalent amount, react for 2 hours, filter the precipitated yellow precipitate, wash with water, ethanol and acetone, and dry at 70°C to obtain Pt(DACH)Cl 2 product with a purity of ≥98 %.
3.Ag2C2O4(市售,分析纯)3.Ag 2 C 2 O 4 (commercially available, analytically pure)
4.KI(分析纯),乙醇(分析纯),丙酮(分析纯)。4. KI (analytical pure), ethanol (analytical pure), acetone (analytical pure).
具体实施方式Detailed ways
实施例1Example 1
5克Pt(DACH)Cl2溶于适量去离子水中,温度控制在40℃左右,等当量加入Ag2C2O4,避光搅拌反应6小时,然后过滤除去AgCl沉淀,母液减压浓缩,得到4.2克白色结晶样品,产率为81%。经元素分析、红外等分析,结构与目标化合物一致。Dissolve 5 grams of Pt(DACH)Cl 2 in an appropriate amount of deionized water, control the temperature at about 40°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 6 hours in the dark, then filter to remove the AgCl precipitate, and concentrate the mother liquor under reduced pressure. A 4.2 g sample of white crystals was obtained with a yield of 81%. The structure was consistent with the target compound by elemental analysis and infrared analysis.
元素分析:测定值为C:24.21%,H:3.57%,N:7.01%,Pt:49.04%。理论值为C:24.19%,H:3.55%,N:7.05%,Pt:49.09%。组成与理论吻合。Elemental analysis: measured values are C: 24.21%, H: 3.57%, N: 7.01%, Pt: 49.04%. Theoretical values are C: 24.19%, H: 3.55%, N: 7.05%, Pt: 49.09%. The composition agrees with the theory.
红外吸收光谱:IR光谱(KBr压片cm-1):N-H(3212,3171,1610);C-H(3095,2932,2863,1447);C=O(1702,1664);C-O(1379);C-C(916,909);Pt-N(480);Pt-O(310)。Infrared absorption spectrum: IR spectrum (KBr pellet cm -1 ): NH (3212, 3171, 1610); CH (3095, 2932, 2863, 1447); C=O (1702, 1664); CO (1379); CC (916,909); Pt-N (480); Pt-O (310).
质谱(MS):采用快原子轰击法,测定结果见表1。Mass Spectrometry (MS): The fast atom bombardment method was adopted, and the measurement results are shown in Table 1.
表1
实施例2Example 2
5克Pt(DACH)Cl2溶于适量去离子水中,温度控制在75℃左右,等当量加入Ag2C2O4,避光搅拌反应4小时,然后过滤除去AgCl沉淀,母液减压浓缩,得到4.12克白色结晶样品,产率为79%。经元素分析、红外、质谱等分析,结构与目标化合物一致。Dissolve 5 grams of Pt(DACH)Cl 2 in an appropriate amount of deionized water, control the temperature at about 75°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 4 hours in the dark, then filter to remove the AgCl precipitate, and concentrate the mother liquor under reduced pressure. A 4.12 g sample of white crystals was obtained with a yield of 79%. The structure is consistent with the target compound by elemental analysis, infrared, mass spectrometry and other analysis.
元素分析:测定值为C:24.23%,H:3.56%,N:7.04%,Pt:49.12%。理论值为C:24.19%,H:3.55%,N:7.05%,Pt:49.09%。组成与理论吻合。Elemental analysis: measured values are C: 24.23%, H: 3.56%, N: 7.04%, Pt: 49.12%. Theoretical values are C: 24.19%, H: 3.55%, N: 7.05%, Pt: 49.09%. The composition agrees with the theory.
红外吸收光谱:IR光谱(KBr压片cm-1):N-H(3217,3176,1613);C-H(3099,2936,2867,1450);C=O(1710,1669);C-O(1382);C-C(917,912);Pt-N(480):Pt-O(310)。Infrared absorption spectrum: IR spectrum (KBr pellet cm -1 ): NH (3217, 3176, 1613); CH (3099, 2936, 2867, 1450); C=O (1710, 1669); CO (1382); CC (917,912); Pt-N(480):Pt-O(310).
质谱(MS):采用快原子轰击法,测定结果见表2。Mass Spectrometry (MS): The fast atom bombardment method was adopted, and the measurement results are shown in Table 2.
表2
实施例3Example 3
5克Pt(DACH)Cl2溶于适量去离子水中,温度控制在55℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品4.21克,结构与目标化合物一致,产率为81%。Dissolve 5 grams of Pt(DACH)Cl 2 in an appropriate amount of deionized water, control the temperature at about 55°C, add an equivalent amount of Ag 2 C 2 O 4 , and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1, and sample 4.21 is obtained. gram, the structure is consistent with the target compound, and the yield is 81%.
实施例4Example 4
9克Pt(DACH)I2溶于适量去离子水中,温度控制在40℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品5.12克,结构与目标化合物一致,产率为82%。Dissolve 9 grams of Pt(DACH)I 2 in an appropriate amount of deionized water, control the temperature at about 40°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1, and sample 5.12 is obtained. gram, the structure is consistent with the target compound, and the yield is 82%.
实施例5Example 5
9克Pt(DACH)I2溶于适量去离子水中,温度控制在75℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品5.02克,结构与目标化合物一致,产率为80.5%。Dissolve 9 grams of Pt(DACH)I 2 in an appropriate amount of deionized water, control the temperature at about 75°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1 to obtain sample 5.02 gram, the structure is consistent with the target compound, and the yield is 80.5%.
实施例6Example 6
9克Pt(DACH)I2溶于适量去离子水中,温度控制在55℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品5.19克,结构与目标化合物一致,产率为83.1%。Dissolve 9 grams of Pt(DACH)I 2 in an appropriate amount of deionized water, control the temperature at about 55°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1, and sample 5.19 is obtained. gram, the structure is consistent with the target compound, and the yield is 83.1%.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03103908 CN1221560C (en) | 2003-01-30 | 2003-01-30 | Preparation of oxaliplatin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03103908 CN1221560C (en) | 2003-01-30 | 2003-01-30 | Preparation of oxaliplatin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1521161A true CN1521161A (en) | 2004-08-18 |
CN1221560C CN1221560C (en) | 2005-10-05 |
Family
ID=34282115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03103908 Expired - Fee Related CN1221560C (en) | 2003-01-30 | 2003-01-30 | Preparation of oxaliplatin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1221560C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114441671A (en) * | 2021-12-23 | 2022-05-06 | 北京悦康科创医药科技股份有限公司 | Method for determining content of platinum impurity cyclohexanediamine dihydrate in oxaliplatin by combination of HPLC-ICP-MS |
-
2003
- 2003-01-30 CN CN 03103908 patent/CN1221560C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114441671A (en) * | 2021-12-23 | 2022-05-06 | 北京悦康科创医药科技股份有限公司 | Method for determining content of platinum impurity cyclohexanediamine dihydrate in oxaliplatin by combination of HPLC-ICP-MS |
CN114441671B (en) * | 2021-12-23 | 2023-05-30 | 北京悦康科创医药科技股份有限公司 | Method for measuring content of cyclohexanediamine dihydrate platinum impurities in oxaliplatin by HPLC-ICP-MS (high performance liquid chromatography-inductively coupled plasma-mass spectrometry) combination |
Also Published As
Publication number | Publication date |
---|---|
CN1221560C (en) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Canil et al. | Photocytotoxic Pt (iv) complexes as prospective anticancer agents | |
HK1055746A1 (en) | Process of preparing platinum compound | |
CN1285603C (en) | Synthesis of oxaliplatin | |
CN1196706C (en) | Method for preparing platinum compound | |
CN1221560C (en) | Preparation of oxaliplatin | |
CN101830933B (en) | Novel method for synthesizing antitumor medicament platinum | |
CN101768191A (en) | Novel method for synthesizing anti-tumor drug Miriplatin | |
CN1948323A (en) | Platinum (II)- anticancer compound using 2-hydroxy-1,3-propane diamine as carrier group | |
CN101918379B (en) | Platinum complex compound and utilization of the same | |
CN106883251A (en) | A kind of many pyridine copper complexes of amino acid and its preparation method and application | |
CN114106052A (en) | Tetranuclear platinum carboxylate, synthetic method and application thereof in preparation of platinum black | |
WO2021051709A1 (en) | Osmium complex, preparation method therefor and use thereof | |
CN100582115C (en) | Novel method for synthesizing antineoplastic medicine carboplatin | |
CN101234788A (en) | Method for synthesizing antineoplastic medicine cisplatin | |
CN114437133B (en) | Iridium-containing complex and preparation method thereof | |
JP2007512318A (en) | Platinum (II) complex and process and use of the complex | |
RU2457838C1 (en) | Method of obtaining trans-1,2-diaminocyclohexane tetrachloroplatinum (iv) | |
CN101343291B (en) | Novel method for preparing oxaliplatin | |
CN101302236A (en) | Novel method for synthesizing antineoplastic medicine nedaplatin | |
JP2012530737A (en) | Process for producing 1,2-diamino-cyclohexane-platinum (II) complex | |
CN1203080C (en) | Antitumour platinum (II) compound using camphor acid radical as ligand | |
CN1260221C (en) | Method for preparing platinum(II) metal complex eptaplatin | |
CN101475599B (en) | Novel method for synthesizing antineoplastic medicament nedaplatin | |
CN1263764C (en) | Platinum complex having anticancer activity | |
CN105218589A (en) | A kind of synthetic method of oxaliplatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051005 Termination date: 20150130 |
|
EXPY | Termination of patent right or utility model |